Multimodal Imaging Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

The Multimodal Imaging market is expected to grow from USD 4.38 billion in 2025 to USD 4.59 billion in 2026 and is forecast to reach USD 5.82 billion by 2031 at 4.86% CAGR over 2026-2031. Growth is shaped by health-system emphasis on hybrid diagnostic platforms that merge anatomical and functional data, strengthening early detection and treatment-monitoring accuracy in oncology and cardiology. Artificial-intelligence overlays automate scan protocols, shorten exam times, and elevate diagnostic confidence, while regulatory approvals for next-generation devices accelerate market adoption. North America retains leadership through robust reimbursement and wide theranostic radiopharmaceutical use, yet Asia-Pacific delivers the fastest trajectory on the back of hospital modernization, chronic-disease burden, and expanding private healthcare investment. The competitive field remains moderately consolidated around GE Healthcare, Siemens Healthineers, and Philips, each leveraging cloud-based analytics to differentiate performance and reduce ownership costs. Persistent headwinds—capital intensity, isotope-supply volatility, and data-integration hurdles—temper the otherwise positive outlook for the multimodal imaging market.

Rising incidence of cancer and cardiovascular disorders keeps demand for sophisticated diagnostics high. Multimodal imaging delivers metabolic–anatomical correlation that single-modality exams cannot match, positioning the modality at the centre of preventive-care strategies. Cardiovascular MRI contributed measurable cost savings and outcome gains in a 361-patient study, underscoring health-economic value. Utilisation is projected to climb 27% in 30 years, reflecting demographic ageing and expanding clinical protocols rather than population growth alone. Oncology PET/CT volumes will benefit directly, as metabolic mapping improves early tumour detection and response assessment. The sustained rise in non-communicable disease prevalence therefore injects durable momentum into the multimodal imaging market.

Hybrid scanners now integrate AI to automate protocols and sharpen image clarity. Siemens Healthineers’ Biograph Horizon employs 4 × 4 mm LSO crystals and true time-of-flight, delivering high-resolution studies at reduced dose. Total-body PET enables dynamic acquisition, producing superior contrast while shrinking acquisition windows. Philips and NVIDIA jointly built MR foundation models that allow “zero-click” planning, promoting reproducibility and faster throughput. Such advances reduce technologist workload, increase scanner utilisation, and strengthen clinical-decision support—elements that fuel uptake across the multimodal imaging market.

Screening programmes now embed multimodal workflows to heighten accuracy. The FDA cleared Lumisight and Lumicell DVS fluorescence guidance for breast-conserving surgery, achieving 84% accuracy in detecting residual disease and cutting re-operation risk. PET/MRI in cervical cancer, augmented by parallel-encoder U-Net, reached a 0.726 Dice score for tumour segmentation. 18F-FES PET combined with 18F-FDG elevates confidence when staging estrogen-receptor-positive breast tumours. These breakthroughs reinforce the pre-eminence of hybrid modalities in oncology and expand the addressable base for the multimodal imaging market.

Cardiac PET/CT distinguishes viable from scarred myocardium, guiding revascularisation and raising quality-adjusted life years at acceptable thresholds. Long-axial field-of-view PET/CT reduces radiation while enabling faster whole-body studies, beneficial for unstable cardiac patients. AI-driven quantification packages accelerate perfusion analysis and standardise reporting. Together, these factors integrate cardiac PET/CT deeper into routine cardiology pathways, broadening revenue streams for the multimodal imaging market. Integration with AI-powered analysis platforms streamlines workflow efficiency while maintaining diagnostic accuracy standards required for clinical decision-making.

Hybrid scanners require multi-million-dollar outlays and specialised upkeep, hampering acquisition in budget-constrained settings. Emergency-department studies show that although multimodal CT elevates diagnostic certainty for dizziness, economic burden deters blanket implementation.^{[1]Source: Long H. Tu, “Cost-Effectiveness of CT, CTA, MRI…,” PUBMED.NCBI.NLM.NIH.GOV} Reimbursement frameworks often trail innovation, amplifying payback risk and limiting diffusion across the multimodal imaging market. The diagnostic imaging market faces consolidation pressures as providers seek economies of scale to manage these cost challenges while maintaining service quality standards.

Power-supply variability, cooling requirements, and limited engineering workforces restrict hybrid technology roll-outs in developing economies. Regulatory diversity further complicates approvals, with decentralised EU pathways contrasting US FDA reviews.^{[2]Source: Long H. Tu, “Cost-Effectiveness of CT, CTA, MRI…,” PUBMED.NCBI.NLM.NIH.GOV} Training gaps intensify deployment challenges, slowing growth in the multimodal imaging market across underserved geographies. These infrastructure gaps particularly affect rural and underserved populations where portable solutions offer the most significant potential impact.